| Deal Structure and Party Summary | ||
|---|---|---|
| Deal Structure | Private Target Merger | |
| Acquirer | Organon & Co. | |
| Public | Yes | |
| Industry | Healthcare | |
| Private equity sponsorship | No | |
| Target | Dermavant Sciences Ltd. | |
| Public | No | |
| Industry | Healthcare | |
| Private equity sponsorship(s) | No | |
| Key Transaction Characteristics and Terms | ||
|---|---|---|
| Status | Pending | |
| Announcement date | September 18, 2024 | |
| Transaction value | $1.2 billion | |
| Form of consideration | Cash | |
| Type of merger | Reverse Triangular | |
| Go-Shop/No-Shop Terms | ||
|---|---|---|
| No-Shop Provision | Yes | |
| Go-shop Provision | No | |
| Transaction Advisors | ||
|---|---|---|
| Seller / Target Counsel | ||
| Law firm #1 | Freshfields Bruckhaus Deringer LLP | |
| Individual attorney(s) |
Damien R. Zoubek; Jenny Hochenberg; Tomas T.J. Rua |
|
| Acquirer Counsel | ||
| Law firm #1 | Covington & Burling LLP | |
| Individual attorney(s) |
Catherine Dargan; Patrick Manchester |
|
| Seller / Target Financial Advisors | ||
| Financial advisor #1 | Goldman Sachs & Co LLC | |